

Journal of

Drug and Alcohol Research

The Official Journal of The International Drug Abuse Research Society



ISSN 2090-8134
e-ISSN 2090-8141

EDITORIAL BOARD

Editor/Editor

Kinjal J. Parikh, Ph.D. in Pharmacy
Professor, Pharmacy
The Maharaja Sayajirao University of Baroda, India

ASSOCIATE EDITORS

Syed F. Ali
National Center for Toxicological Research
United States

Jesus A. Angulo
City University of New York, United States

Eliot L. Gardner
Intramural Research Program of the National Institute
United States

Valentina G. Bashkatova
P. K. Anokhin Institute of Normal Physiology
Russia

Antonello Bonci
National Institute on Drug Abuse
United States

Herminia Alicia Brusco
University of Buenos Aires, Argentina

Jean-Lud Cadet
National Institutes of Health
United States

F lix Carvalho
University of Porto, Portugal

Jian-Guo Chen
Huazhong University of Science and Technology, China

Marco Diana
University of Sassari, Italy

Peter R. Dodd
The University of Queensland, Australia

Katia Gysling
Pontificia Universidad Cat lica de Chile
Chile

Glen R. Hanson
University of Utah, United States

Carlos A. Jim nez-Rivera
University of Puerto Rico, Puerto Rico

Peter W. Kalivas
The Medical University of South Carolina, United States

Hyoungh-Chun Kim
Kangwon National University, South Korea

George F. Koob
The Scripps Research Institute
United States

Barbara Mason
The Scripps Research Institute
United States

John E. Mendelson
California Pacific Medical Center Research Institute
United States

John E. Mendelson
California Pacific Medical Center Research Institute
United States

Diane B. Miller
Centers for Disease Control and Prevention
United States

Eric J. Nestler
Mount Sinai School of Medicine
United States

James P. O'Callaghan
CDC/NIOSH
United States

M. Foster Olive
Arizona State University, United States

Merle G. Paule
National Center for Toxicological Research
United States

Sakire Pogun
Ege University, Turkey

Marcus Rattray
University of Reading, United Kingdom

Abel Santamar a
National Institute of Neurology and Neurosurgery
Mexico

Alois Saria
Medical University Innsbruck, Austria

Susan Schenk
Victoria University of Wellington, New Zealand

Aristidis M. Tsatsakis
University of Crete, Greece

Yousef Tizabi
Howard University College of Medicine, United States

George R. Uhl
National Institutes of Health
United States

Ming Xu
The University of Chicago, United States

EDITORIAL BOARD

Editorial and Advisory Board

Redi Panuju, PhD

Professor, Department of Communication
Dr Soetomo University, Indonesia

Asmaa F. Hamouda, PhD

Professor, Department of Biochemistry
Alexandria University, Egypt, Egypt

Michael J. Kuhar

Emory University, United States

DEPUTY EDITOR

Emilio Ambrosio

National Distance Learning University, Spain

Editor-in-Chief

Amgad Rabie, MD

Head of Clinical Research Department at Dikernis General Hospital
Mansoura University, Egypt

Junzheng Yang

Director, Pharmacology Department
Guangdong nephrotic drug Engineering Technology Research Center, China

Emmanuel Onaivi

William Paterson University, United States

Kazutaka Ikeda

Tokyo Metropolitan Institute of Medical Science
Japan

Kiyofumi Yamada

Nagoya University, Japan

2023: Volume 12, Issue 5

The Experiences of Families of Adolescents who use Substances at a Township in Mpumalanga Province, South Africa

Kebogile Mokwena* and Lamasonto Ndhlovu

Volume 12 (2023)

DOI: 10.4303/JDAR/236241

Published: June, 2023

[Abstract](#)

[HTML](#)

[PDF](#)

Effects of Valproic Acid on Pregnancy in Epilepsy Patients

Triasti Khusfiani, Yudhisman Imran*, Irmiya Rachmiyani and Donna Adriani

Volume 12 (2023)

DOI: 10.4303/JDAR/236245

Published: June, 2023

[Abstract](#)

[HTML](#)

[PDF](#)

Drug Development and Validation of a Sensitive Bio-analytical LCMS/MS Method for Quantification of Asciminib-a Chronic Myeloid Leukemia Drug in Human Plasma

Govindarao Yedlapalli* and Y. Ganesh Kumar

Volume 12 (2023)

DOI: 10.4303/JDAR/236242

Published: June, 2023

[Abstract](#)

[HTML](#)

[PDF](#)

Design and Characterization of Dolutegravir Sodium Loaded Solid Lipid Nano Particles

Prasanth Y*, S. Madhusudhan, Shaik Harun Rasheed and P. Yeera Lakshmi

Volume 12 (2023)

DOI: 10.4303/JDAR/236243

Published: June, 2023

[Abstract](#)

[HTML](#)

[PDF](#)

Progressive Innovations in Advanced Functional Materials for Emerging Bio-electronics, Drugs Sensing and Healthcare

Iqra Qayyum*, Fazal Ur Rehman, Manzar Zahra, Kanwal Batool, Waseem Shoukat, Sabeen Arshad, Shahid Anwar, Aoun Raza and Zeshan Zada

Volume 12 (2023)

DOI: 10.4303/JDAR/236244

Published: June, 2023

[Abstract](#)

[HTML](#)

[PDF](#)

Research Article

Effects of Valproic Acid on Pregnancy in Epilepsy Patients

Triasti Khusfiani¹, Yudhisman Imran^{2*}, Irmiya Rachmiyani³, Donna Adriani⁴

¹Department of Pharmacology, Universitas Trisakti, Indonesia

²Department of Neurology, Universitas Trisakti, Indonesia

³Department of Obstetrics and Gynecology, Universitas Trisakti, Indonesia

⁴Department of Physiology, Universitas Trisakti, Indonesia

*Address Correspondence to Yudhisman Imran, E-mail: yudhisman.imran@trisakti.ac.id

Received: 31 May 2023; Manuscript No: JDAR-23-104878; **Editor assigned:** 02 June 2023; PreQC No: JDAR-23-104878 (PQ); **Reviewed:** 16 June 2023; QC No: JDAR-23-104878; **Revised:** 21 June 2023; Manuscript No: JDAR-23-104878 (R); **Published:** 28 June 2023; **DOI:** 10.4303/JDAR/236245

Copyright © 2023 Triasti Khusfiani, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Valproic acid has long proven to be an effective drug for treating epilepsy and has been prescribed to pregnant women with epilepsy ever since. There are only few prospective studies regarding this drug during pregnancy, however several cohort studies have shown that women taking it during the first trimester have an increased risk of congenital disorders such as spina bifida, craniosynostosis, cleft palate, hypospadias, and more. Valproic acid also has a postnatal developmental disorder effect such as ADHD and ASD in children who were exposed to it before birth. Concerns about valproic acid and its teratogenic risks has led many women to discontinue their antiepileptic medication either before pregnancy or early in their pregnancy. Even though it is highly recommended to minimize or even discontinue valproic acid use in pregnancy, but in some cases, the risks of discontinuing this drug may outweigh the benefits. When valproic acid was discontinued in the first trimester (the most teratogenic period) it was associated with a significantly higher incidence of generalized tonic-clonic seizures than when it was continued (33% vs 16%). Furthermore, if valproic acid is substituted for another antiepileptic drug, seizure incidence could increase by 29%. Using valproic acid during pregnancy for epilepsy patients is a growing problem where patients and doctors will be faced with a situation where they must consider in detail the benefits and risks of using this drug.

Keywords: Valproic acid; Epilepsy; Pregnancy

Introduction

Since its anticonvulsant qualities were discovered more than 5 decades ago, valproic acid has been proven to be a successful treatment for epilepsy [1]. The Food and Drug Administration (FDA) authorized valproic acid in 1978 as a monotherapy and as an additional therapy for various types of seizures which can also be used to treat bipolar disorder and prevent migraines [2]. Valproic acid's effectiveness in treating epilepsy has been extensively studied in various observational and RCT (Randomized Controlled Trials) studies which stated that because of its broad-spectrum action against practically all types of seizures, valproic acid is more superior and preferable to other antiepileptic

medications [3,4]. Despite the fact that it is not the sole anti-epileptic medication that is presently most frequently administered, valproic acid still remains one of the most effective medications. This medication is strongly recommended when other anticonvulsants are inadequate, and also as a first-line treatment for complex partial seizures. It is also used in emergency situations to control focal and generalized seizures [5].

Epilepsy is a neurological condition that is often found in pregnant women with a prevalence of 0.5%-1% [6]. In Indonesia, there is no definite data regarding the incidence of epilepsy in pregnancy. But in the United States, it is said that around 3-5 out of 1,000 births are delivered by women with epilepsy. Meanwhile, of all the pregnant women, it was found that between 0.3%-0.5% were women with epilepsy [7]. A study in the United Kingdom showed that out of all antiepileptic drugs that have been prescribed to pregnant women, about 25% are valproic acid [8]. Various studies stated that valproic acid does have a fairly high teratogenic risk. Over the past decade, new facts have emerged concerning the risks of congenital abnormalities and postnatal developmental problems in children exposed prenatally to valproic acid. These risks raise concerns about the efficacy of valproic acid as a first-line therapy for epilepsy in females of reproductive age. Despite being aware of its teratogenic risk, valproic acid was still prescribed to 20% of pregnant epileptic women between the year 1999 and 2004, according to data from EURAP (International Registry of Anti-Epileptic Drugs and Pregnancy) [9,10]. In 2018, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency advised against using valproic acid during pregnancy unless the mother has a kind of epilepsy that is resistant to other anti-epileptic medications.

Women of reproductive age who are not involved in a program for preventing pregnancy should also not be given this medicine [11].

Concerns about valproic acid and its teratogenic risks has led many women to discontinue their antiepileptic medication either before pregnancy or early in their pregnancy. However, in some cases this is not recommended because it can greatly increase the chance of experiencing a seizure. Therefore, this review article will provide an overview of the potential risks and benefits of the use of valproic acid among pregnant or prospective pregnant women with epilepsy.

Pharmacology

Mechanism of action

In general, the mechanism action of valproic acid as a therapy for epilepsy can be explained in several ways, such as affecting the levels of GABA (Gamma-Aminobutyric Acid) in the Central Nervous System (CNS), inhibit histone deacetylase enzymes and blocking voltage-gated ion channels [2]. Gamma-Aminobutyric acid (GABA) is an important neurotransmitter that plays a role in specific brain areas associated with seizures. Valproic acid has an effect on the production of GABA, which causes an increase in the levels of this neurotransmitter in the brain which can prevent seizures. In addition, valproic acid is also considered to be able to enhance the effects of GABA that are already present in the receptor area. Various studies stated that the mechanism action of valproic acid mimics/resembles the action of GABA, thereby reducing the risk of seizures [12]. The Tricarboxylic Acid (TCA) cycle produces GABA from α -ketoglutarate, which is subsequently converted by GABA transaminase and succinic semialdehyde dehydrogenase into succinic semialdehyde and succinic acid, respectively. According to earlier research, valproic acid inhibits succinic semialdehyde dehydrogenase and GABA transaminase, preventing the breakdown of GABA and therefore raising its concentration [2]. There is further speculation that voltage-gated sodium and calcium channels are crucial for the role in the action of valproic acid. Valproic acid can reduce Ca^{2+} ion activity and prolong the recovery of voltage-gated Na^{+} channels. However, the role of valproic acid on K^{+} channel conductance is still controversial. Although the exact methods are not yet clearly established, observational studies suggest that these pathways in the brain are likely to impact the onset of some types of seizures, especially absence seizures [2,11].

These numerous mechanisms can provide an explanation for its extensive spectrum activity, its other indications besides for epilepsy, namely for migraines and mood disorders, as well as its potential use for new indications such as cancer therapy and prevention, which are currently being studied [13].

Pharmacokinetics

Valproic acid is well absorbed after oral administration, with a bioavailability of over 80%. Peak levels are reached within 2 hours (1 hour to 4 hours). Food can slow absorp-

tion and will decrease toxicity if the drug is administered after meals. Valproic acid has a pKa of 4.7 so it ionizes completely at physiological pH plasma. The drug also binds 90% to plasma proteins, but the amount of binding decreases when blood concentrations exceed 150 $\mu\text{g/ml}$. Because valproate is completely ionized and binding to plasma proteins, it is dispersed in extracellular water with a V_d (volume of distribution) of about 0.15 L/kg. Valproic acid is fully ionized and binds to plasma proteins, so it is dispersed in extracellular water with a V_d (volume of distribution) of approximately 0.15 L/kg. Valproic acid is mostly (95%) metabolized in the liver and less than 5% is excreted in its original form. Valproate clearance is considered very slow, with a half-life of around 9 hours-18 hours. Clearance of valproate is dose-dependent when at a completely excessive blood levels. About 20% of the drug is directly excreted as valproate conjugate. The remainder is converted into various compounds metabolized by beta and omega oxidants, which eventually be conjugated and excreted [14].

Valproic Acid Dosage and Toxicity

The starting daily dose of valproic acid is generally 15 mg/kg. At a weekly interval this starting dose may be increased by 5 mg/kg to 10 mg/kg, but still not to exceed 60 mg/kg which is its maximum daily dose. In some patients, doses of 25 mg/kg-30 mg/kg daily are sufficient, while others may require doses of 60 mg/kg or more. Valproate has a therapeutic concentration of 50 $\mu\text{g/ml}$ to 100 $\mu\text{g/ml}$. Data from several efficacy studies indicate that drug administration should not be discontinued until peak morning levels are at least 80 $\mu\text{g/mL}$. However, some patients require and tolerate peak levels above 100 $\mu\text{g/mL}$ [14]. The most common side effects of valproic acid are gastrointestinal symptoms which includes anorexia, nausea, vomiting that occurs in about 16% of patients. Other CNS effects include sedation, ataxia, and tremors. These symptoms are rare and usually decrease as the dose is reduced. Rashes, alopecia, and appetite stimulation may also occur occasionally. Valproic acid has some effects on liver function, with up to 40% of patients having elevated plasma liver enzymes, which are often asymptomatic during the first few months of treatment [15]. This hepatotoxic effect is generally reversible when treatment is discontinued. However, this can get worse, so it is necessary to monitor liver function when using valproic acid. In addition, another rare idiosyncratic response can occur, namely thrombocytopenia [14].

Valproic Acid in Epilepsy

Valproic acid has been proven to be an effective therapy for generalized epilepsy, and is considered the first-line drug for nearly all epilepsy syndromes unless there are specific contraindications. In a one large study of adults and children with generalized or unclassified epilepsy, the efficacy and tolerability of valproic acid was significantly better than that of lamotrigine or topiramate [16]. Status epilepticus can also be treated with valproic acid and despite its lack of high-quality trial research, the evidence that is currently available implies that for patients with status epilep-

ticus who cannot be treated with benzodiazepines, valproic acid can be given as an effective and a safe treatment option [17].

Pregnancy in Epilepsy Patients

Pregnancy is related to physiological, endocrine and psychological changes that can lead to a decrease in the seizure threshold [18,19]. The concept of seizure threshold holds that everybody has a stability among excitatory and inhibitory forces within side the brain. A low seizure threshold makes epilepsy to develop easily and less harder for a person to elicit a seizure. The opposing outcomes of oestrogen (proconvulsant) and progesterone (anticonvulsant) on seizure threshold were proven in animal and human studies. Oestrogen has also been proven to decrease the seizure threshold [20]. The frequency of seizures in pregnancy can increase because of multiple reasons such as changes in oestrogen and progesterone levels, increased water and sodium retention, stress related with pregnancy, changes in the pharmacokinetics of anti-epileptic drugs and physiological factors such as sleep deprivation. One of the factors that can predict the amount of seizures that can happen during pregnancy, is the frequency of seizures that occurred 1 year before pregnancy [18].

Concentrations of antiepileptic drugs in plasma can vary due to physiological changes such as in the absorption process, hepatic clearance, increased renal clearance and plasma volume distribution and also induction of liver enzymes. In pregnancy, drug absorption can be impaired because of reduced gastric tone and motility. Changes in the activity of enzymes in the liver that play a role in drug metabolism, blood flow, and drug transporters can affect the hepatic clearance of antiepileptic drugs. This is very important because some antiepileptic drugs are metabolized by Nicotinamide Adenine Dinucleotide Phosphate (NADPH) cytochrome P450 reductase, Uridine Diphosphatase Glucose (UDP) glucuronosyltransferase, and then excreted *via* the kidneys [21]. The risk of death from pregnancy in a woman is ten times greater for those who have a history of epilepsy than for those who don't. Aside from that, it has been reported that as many as 12 out of 14 cases of maternal death that occurred from 2009 to 2012, were classified as a Sudden Unexpected Death in Epilepsy (SUDEP) with uncontrolled seizures being the main cause [6].

Therefore, out of consideration of their own health and that of their child, women who have a history of epilepsy are strongly advised to continue their treatment with antiepileptic drugs during their pregnancy. According to a study conducted by Schmidt and Schachter which stated that although about two-thirds of pregnant women with epilepsy do not have seizures during their pregnancy, the dosage of anti-epileptic drugs need to be adjusted as pregnancy goes on, particularly if seizures occur during the first 3 months of pregnancy [5].

Discussion Effects of valproic acid in pregnancy

There are only few prospective studies on the effects of valproic acid during pregnancy, however many cohort studies

have demonstrated a 7-fold increased risk of congenital malformations in women using this medication during the first trimester of pregnancy [22]. When compared to individuals who were not receiving antiepileptic medications, patients who received valproic acid as a monotherapy in the first trimester had a significantly higher risk of spina bifida, craniosynostosis, cleft palate, hypospadias, atrial septal defect, and polydactyly [23,24]. According to estimates, these risks affect 10%–11% of newborn from women with epilepsy, compared to just 2%–3% of the general population. The causes of these teratogenic reactions are not fully elucidated, but may include epigenetic alterations, such as inhibition of histone dehydrogenase with associates with alterations in gene expression, heightened oxidative stress, or inhibition of folate, which is necessary for DNA synthesis [25,26].

In addition to its teratogenic effects, valproic acid can cause various problems after birth. Some studies say that between 30% and 40% of children who has been exposed to valproic acid since the second and the third trimester of pregnancy can lead to cause alterations in cognitive functioning and behaviour, and also a higher chance of having neurological disorders, particularly ADHD and ASD [27]. According to research conducted in Denmark, the probability of ASD in children exposed to valproic acid is 3 times-5 times higher than in the general population. Cohen et al. also identified the chance of developing Attention Deficit Hyperactivity Disorder (ADHD) in 21% of children ages 6 years and above who had been exposed to prenatal valproic acid [28,29]. Furthermore, in a 2004 retrospective study, it was concluded that prenatal intake of valproic acid may have an impact on the intellectual development of children where these children had significantly lower verbal intelligence (IQ) scores than those exposed to carbamazepine, phenytoin, or those who were never expose to any antiepileptic drugs [30]. Several factors may contribute to the clinical effect for mothers and children expose to valproic acid, namely the frequency and duration of seizures, the need for additional drug treatments to control epilepsy, the use of drugs and alcohol, comorbidities, sociocultural factors, and also the stage of pregnancy the woman is in [5].

It is recommended to discontinue treatment with valproic acid during pregnancy, particularly during the initial trimester. Nevertheless, there are some potential risks associated with the discontinuation of this drug in patients with well controlled epilepsy [5]. The EURAP study showed that the discontinuation of therapy in the initial trimester (the most teratogenic trimester) was associated with significantly higher rates of generalized tonic-clonic seizure (33%) compared to the continuation of treatment (16%). It is even more concerning to note that the prevalence of seizures may be increased (29%) when valproic acid is switched to another anti-epileptic drug [31]. The prevention of major birth defects in the fetus can be achieved by administering folic acid supplements, but in the case of women with epilepsy, there is still not enough data to determine its effectiveness. However, giving folic acid is still recommended for all women of reproductive age with or

without epilepsy before conception and during pregnancy at a dose of 0.4 mg per day [32].

In users of valproic acid it is also recommended to check serum alpha-fetoprotein levels (at week 14-16 of pregnancy), ultrasound examination (at week 16-20 of pregnancy) and amniocentesis to check levels of alpha-fetoprotein and anticholinesterase in amniotic fluid [21]. If there are abnormalities in any of the examinations above, continuing the pregnancy or not has to be considered thoroughly. Use of the lowest possible daily dose divided into 3 doses to minimize fluctuations in serum valproic acid levels can also lower the risk of fetal harm. It has been observed that higher daily doses of 1000 mg or more, as well as combination with other therapy (polytherapy), are related to a greater risk of teratogenicity. Additionally, it has been observed that certain other antiepileptic drugs may enhance the teratogenicity of valproic acids. Therefore, if it is necessary to use valproic acid during pregnancy, the most effective dosage should be prescribed in 2 to 3 doses, and ideally as a monotherapy [25].

Conclusion

Using valproic acid in pregnant women with epilepsy is a growing problem. Valproic acid has the highest teratogenic risk compared to other antiepileptic drugs. Not only that, postnatal abnormalities in the form of cognitive and behavioural abnormalities can also be experienced by foetuses exposed to valproic acid. In summary, it is highly recommended to minimize or even discontinue valproic acid use in pregnancy, but in some cases, the risks of discontinuing this drug may outweigh the benefits. Therefore, patients and doctors will be faced with a situation where they must consider in detail the benefits and risks of using this drug.

Acknowledgement

None.

Conflict of Interest

Authors have no conflict of interest to declare.

References

1. T. Tomson, D. Battino, E. Perucca, Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug, *Lancet Neurol*, 15(2016):210-218.
2. M. Rahman, H. Nguyen, Valproic acid-statpearls, *Stat-Pearls*, 2022.
3. E. Perucca, Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience, *CNS Drugs*, 16(2002):695-714.
4. T. Glauser, E. Ben-Menachem, B. Bourgeois, A. Cnaan, C. Guerreiro, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes, *Epilepsia*, 54(2013):551-563.
5. A. Macfarlane, T. Greenhalgh, Sodium valproate in pregnancy: What are the risks and should we use a shared decision-making approach? *BMC Pregnancy Childbirth*, 18(2018):200.
6. Royal College of Obstetrician and Gynecologists, Epilepsy in pregnancy (green-top guideline No. 68), 2016.
7. C.L. Harden, J. Hopp, T.Y. Ting, P.B. Pennell, J.A. French, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American academy of neurology and the American epilepsy society, *Epilepsia*, 50(2009):1229-1236.
8. I. Petersen, S.L. Collings, R.L. McCrea, I. Nazareth, D.P. Osborn, et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: Comparative prevalence studies, *Clin Epidemiol*, 9(2017):95-103.
9. T. Tomson, A. Marson, P. Boon, M.P. Canevini, A. Covanis, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential, *Epilepsia*, 56(2015):1006-1019.
10. EURAP Study Group, Seizure control and treatment in pregnancy: Observations from the EURAP epilepsy pregnancy registry, *Neurology*, 66(2006):354-60.
11. A. Wieck, S. Jones, Dangers of valproate in pregnancy, *BMJ*, 11(2018):361.
12. W. Löscher, Basic pharmacology of valproate a review after 35 years of clinical use for the treatment of epilepsy, *CNS Drugs*, 16(2002):669-94.
13. S.A. Brodie, J.C. Brandes, Could valproic acid be an effective anticancer agent? The evidence so far, *Expert Rev Anticancer Ther*, 14(2014):1097-1100.
14. B. Katzung, Basic & clinical pharmacology, 13th ed, (Trevor A, ed.), McGraw Hill; 2015.
15. L. Brunton, R. Hilal-Dandan, Goodman & Gilman's: The pharmacological basis of therapeutics, 13th ed, (Knollmann B, ed.), McGraw-Hill, 2017.
16. A.G. Marson, A.M. Al-Kharusi, M. Alwaidh, R. Appleton, G.A. Baker, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial, *Lancet*, 369(2007):1016-1026.
17. E. Trinka, J. Höfler, A. Zerbs, F. Brigo, Efficacy and safety of intravenous valproate for status epilepticus: A systematic review, *CNS Drugs*, 28(2014):623-639.
18. S. Thomas, Management of epilepsy and pregnancy, *J Postgrad Med*, 52(2006):57-64.
19. S.I. Patel, P.B. Pennell, Management of epilepsy during pregnancy: An update, *Ther Adv Neurol Disord*, 9(2016):118-129.

20. H. Harsono, Seizure threshold, hormones and anti-epileptic drugs, *Universa Medicina*, 27(2008): 18-28.
21. Fidelia, J. Nainggolan, Epilepsi dalam kehamilan, *Medicinus*, 7(2018):61-69.
22. D. Wyszynski, M. Nambisan, T. Surve, R. Alsdorf, C. Smith, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy, *Neurology*, 64(2005):961-5.
23. J. Jentink, M.A. Loane, H. Dolk, I. Barisic, E. Garne, et al. Valproic acid monotherapy in pregnancy and major congenital malformations, *N Engl J Med*, 362(2010):2185-93.
24. K. Meador, M.W. Reynolds, S. Crean, K. Fahrbach, C. Probst, Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts, *Epilepsy Res*, 81(2008):1-13.
25. A. Ornoy, Valproic acid in pregnancy: How much are we endangering the embryo and fetus? *Reprod Toxicol*, 28(2009):1-10.
26. A. Semmler, C. Frisch, C. Bleul, D. Smith, L. Bigler, et al. Intrauterine valproate exposure is associated with alterations in hippocampal cell numbers and folate metabolism in a rat model of valproate teratogenicity, *Seizure*, 46(2017):7-12.
27. B. Boobalan, P. Kantharaj, D. Sandhanasamy, S. Mohamad, S. Muthupandian, et al. Early cognitive development in children born to women with epilepsy: A prospective report, *Epilepsia*, 51(2010):2058-2065.
28. J. Christensen, T.K. Grønberg, M. Merete, D. Schendel, E.T. Parner, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism, *JAMA*, 309(2013):1696-1703.
29. M.J. Cohen, K.J. Meador, N. Browning, R. May, G.A. Baker, et al. Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years, *Epilepsy Behav*, 29(2013):308-315.
30. N. Adab, U. Kini, J. Vinten, J. Ayres, G. Baker, et al. The longer term outcome of children born to mothers with epilepsy, *J Neurol Neurosurg Psychiatry*, 75(2004):1575-1583.
31. T. Tomson, D. Battino, E. Bonizzoni, J. Craig, D. Lindhout, et al. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP, *Epilepsia*, 57(2016):e173-e177.
32. Neonatal M, Epilepsy and pregnancy management, *Community of Practice*.

Effects of Valproic Acid on Pregnancy in Epilepsy Patients

by Yudhisman Imran FK

Submission date: 07-Feb-2025 02:52PM (UTC+0700)

Submission ID: 2581935010

File name: effects-of-valproic-acid-on-pregnancy-in-epilepsy-patients.pdf (329.36K)

Word count: 3953

Character count: 21532

Research Article

Effects of Valproic Acid on Pregnancy in Epilepsy Patients

Triasti Khusfiani¹, Yudhisman Imran^{2*}, Irmiya Rachmiyani³, Donna Adriani⁴

¹Department of Pharmacology, Universitas Trisakti, Indonesia

²Department of Neurology, Universitas Trisakti, Indonesia

³Department of Obstetrics and Gynecology, Universitas Trisakti, Indonesia

⁴Department of Physiology, Universitas Trisakti, Indonesia

*Address Correspondence to Yudhisman Imran, E-mail: yudhisman.imran@trisakti.ac.id

Received: 31 May 2023; **Manuscript No:** JDAR-23-104878; **Editor assigned:** 02 June 2023; **PreQC No:** JDAR-23-104878 (PQ); **Reviewed:** 16 June 2023; **QC No:** JDAR-23-104878; **Revised:** 21 June 2023; **Manuscript No:** JDAR-23-104878 (R); **Published:** 28 June 2023; **DOI:** 10.4303/JDAR/236245

Copyright © 2023 Triasti Khusfiani, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Valproic acid has long proven to be an effective drug for treating epilepsy and has been prescribed to pregnant women with epilepsy ever since. There are only few prospective studies regarding this drug during pregnancy, however several cohort studies have shown that women taking it during the first trimester have an increased risk of congenital disorders such as spina bifida, craniosynostosis, cleft palate, hypospadias, and more. Valproic acid also has a postnatal developmental disorder effect such as ADHD and ASD in children who were exposed to it before birth. Concerns about valproic acid and its teratogenic risks has led many women to discontinue their antiepileptic medication either before pregnancy or early in their pregnancy. Even though it is highly recommended to minimize or even discontinue valproic acid use in pregnancy, but in some cases, the risks of discontinuing this drug may outweigh the benefits. When valproic acid was discontinued in the first trimester (the most teratogenic period) it was associated with a significantly higher incidence of generalized tonic-clonic seizures than when it was continued (33% vs 16%). Furthermore, if valproic acid is substituted for another antiepileptic drug, seizure incidence could increase by 29%. Using valproic acid during pregnancy for epilepsy patients is a growing problem where patients and doctors will be faced with a situation where they must consider in detail the benefits and risks of using this drug.

Keywords: Valproic acid; Epilepsy; Pregnancy

Introduction

Since its anticonvulsant qualities were discovered more than 5 decades ago, valproic acid has been proven to be a successful treatment for epilepsy [1]. The Food and Drug Administration (FDA) authorized valproic acid in 1978 as a monotherapy and as an additional therapy for various types of seizures which can also be used to treat bipolar disorder and prevent migraines [2]. Valproic acid's effectiveness in treating epilepsy has been extensively studied in various observational and RCT (Randomized Controlled Trials) studies which stated that because of its broad-spectrum action against practically all types of seizures, valproic acid is more superior and preferable to other antiepileptic

medications [3,4]. Despite the fact that it is not the sole anti-epileptic medication that is presently most frequently administered, valproic acid still remains one of the most effective medications. This medication is strongly recommended when other anticonvulsants are inadequate, and also as a first-line treatment for complex partial seizures. It is also used in emergency situations to control focal and generalized seizures [5].

Epilepsy is a neurological condition that is often found in pregnant women with a prevalence of 0.5%-1% [6]. In Indonesia, there is no definite data regarding the incidence of epilepsy in pregnancy. But in the United States, it is said that around 3-5 out of 1,000 births are delivered by women with epilepsy. Meanwhile, of all the pregnant women, it was found that between 0.3%-0.5% were women with epilepsy [7]. A study in the United Kingdom showed that out of all antiepileptic drugs that have been prescribed to pregnant women, about 25% are valproic acid [8]. Various studies stated that valproic acid does have a fairly high teratogenic risk. Over the past decade, new facts have emerged concerning the risks of congenital abnormalities and post-natal developmental problems in children exposed prenatally to valproic acid. These risks raise concerns about the efficacy of valproic acid as a first-line therapy for epilepsy in females of reproductive age. Despite being aware of its teratogenic risk, valproic acid was still prescribed to 20% of pregnant epileptic women between the year 1999 and 2004, according to data from EURAP (International Registry of Anti-Epileptic Drugs and Pregnancy) [9,10]. In 2018, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency advised against using valproic acid during pregnancy unless the mother has a kind of epilepsy that is resistant to other anti-epileptic medications.

Women of reproductive age who are not involved in a program for preventing pregnancy should also not be given this medicine [11].

Concerns about valproic acid and its teratogenic risks has led many women to discontinue their antiepileptic medication either before pregnancy or early in their pregnancy. However, in some cases this is not recommended because it can greatly increase the chance of experiencing a seizure. Therefore, this review article will provide an overview of the potential risks and benefits of the use of valproic acid among pregnant or prospective pregnant women with epilepsy.

Pharmacology

Mechanism of action

In general, the mechanism action of valproic acid as a therapy for epilepsy can be explained in several ways, such as affecting the levels of GABA (Gamma-Aminobutyric Acid) in the Central Nervous System (CNS), inhibit histone deacetylase enzymes and blocking voltage-gated ion channels [2]. Gamma-Aminobutyric acid (GABA) is an important neurotransmitter that plays a role in specific brain areas associated with seizures. Valproic acid has an effect on the production of GABA, which causes an increase in the levels of this neurotransmitter in the brain which can prevent seizures. In addition, valproic acid is also considered to be able to enhance the effects of GABA that are already present in the receptor area. Various studies stated that the mechanism action of valproic acid mimics/resembles the action of GABA, thereby reducing the risk of seizures [12]. The Tricarboxylic Acid (TCA) cycle produces GABA from α -ketoglutarate, which is subsequently converted by GABA transaminase and succinic semialdehyde dehydrogenase into succinic semialdehyde and succinic acid, respectively. According to earlier research, valproic acid inhibits succinic semialdehyde dehydrogenase and GABA transaminase, preventing the breakdown of GABA and therefore raising its concentration [2]. There is further speculation that voltage-gated sodium and calcium channels are crucial for the role in the action of valproic acid. Valproic acid can reduce Ca^{2+} ion activity and prolong the recovery of voltage-gated Na^{+} channels. However, the role of valproic acid on K^{+} channel conductance is still controversial. Although the exact methods are not yet clearly established, observational studies suggest that these pathways in the brain are likely to impact the onset of some types of seizures, especially absence seizures [2,11].

These numerous mechanisms can provide an explanation for its extensive spectrum activity, its other indications besides for epilepsy, namely for migraines and mood disorders, as well as its potential use for new indications such as cancer therapy and prevention, which are currently being studied [13].

Pharmacokinetics

Valproic acid is well absorbed after oral administration, with a bioavailability of over 80%. Peak levels are reached within 2 hours (1 hour to 4 hours). Food can slow absorp-

tion and will decrease toxicity if the drug is administered after meals. Valproic acid has a pKa of 4.7 so it ionizes completely at physiological pH plasma. The drug also binds 90% to plasma proteins, but the amount of binding decreases when blood concentrations exceed 50 $\mu\text{g}/\text{ml}$. Because valproate is completely ionized and binding to plasma proteins, it is dispersed in extracellular water with a V_d (volume of distribution) of about 0.15 L/kg. Valproic acid is fully ionized and binds to plasma proteins, so it is dispersed in extracellular water with a V_d (volume of distribution) of approximately 0.15 L/kg. Valproic acid is mostly (95%) metabolized in the liver and less than 5% is excreted in its original form. Valproate clearance is considered very slow, with a half-life of around 9 hours-18 hours. Clearance of valproate is dose-dependent when at a completely excessive blood levels. About 20% of the drug is directly excreted as valproate conjugate. The remainder is converted into various compounds metabolized by beta and omega oxidants, which eventually be conjugated and excreted [14].

Valproic Acid Dosage and Toxicity

The starting daily dose of valproic acid is generally 15 mg/kg. At a weekly interval this starting dose may be increased by 5 mg/kg to 10 mg/kg, but still not to exceed 60 mg/kg which is its maximum daily dose. In some patients, doses of 25 mg/kg-30 mg/kg daily are sufficient, while others may require doses of 60 mg/kg or more. Valproate has a therapeutic concentration of 50 $\mu\text{g}/\text{ml}$ to 100 $\mu\text{g}/\text{ml}$. Data from several efficacy studies indicate that drug administration should not be discontinued until peak morning levels are at least 80 $\mu\text{g}/\text{mL}$. However, some patients require and tolerate peak levels above 100 $\mu\text{g}/\text{mL}$ [14]. The most common side effects of valproic acid are gastrointestinal symptoms which includes anorexia, nausea, vomiting that occurs in about 16% of patients. Other CNS effects include sedation, ataxia, and tremors. These symptoms are rare and usually decrease as the dose is reduced. Rashes, alopecia, and appetite stimulation may also occur occasionally. Valproic acid has some effects on liver function, with up to 40% of patients having elevated plasma liver enzymes, which are often asymptomatic during the first few months of treatment [15]. This hepatotoxic effect is generally reversible when treatment is discontinued. However, this can get worse, so it is necessary to monitor liver function when using valproic acid. In addition, another rare idiosyncratic response can occur, namely thrombocytopenia [14].

Valproic Acid in Epilepsy

Valproic acid has been proven to be an effective therapy for generalized epilepsy, and is considered the first-line drug for nearly all epilepsy syndromes unless there are specific contraindications. In a one large study of adults and children with generalized or unclassified epilepsy, the efficacy and tolerability of valproic acid was significantly better than that of lamotrigine or topiramate [16]. Status epilepticus can also be treated with valproic acid and despite its lack of high-quality trial research, the evidence that is currently available implies that for patients with status epilep-

ticus who cannot be treated with benzodiazepines, valproic acid can be given as an effective and a safe treatment option [17].

Pregnancy in Epilepsy Patients

Pregnancy is related to physiological, endocrine and psychological changes that can lead to a decrease in the seizure threshold [18,19]. The concept of seizure threshold holds that everybody has a stability among excitatory and inhibitory forces within side the brain. A low seizure threshold makes epilepsy to develop easily and less harder for a person to elicit a seizure. The opposing outcomes of oestrogen (proconvulsant) and progesterone (anticonvulsant) on seizure threshold were proven in animal and human studies. Oestrogen has also been proven to decrease the seizure threshold [20]. The frequency of seizures in pregnancy can increase because of multiple reasons such as changes in oestrogen and progesterone levels, increased water and sodium retention, stress related with pregnancy, changes in the pharmacokinetics of anti-epileptic drugs and physiological factors such as sleep deprivation. One of the factors that can predict the amount of seizures that can happen during pregnancy, is the frequency of seizures that occurred 1 year before pregnancy [18].

Concentrations of antiepileptic drugs in plasma can vary due to physiological changes such as in the absorption process, hepatic clearance, increased renal clearance and plasma volume distribution and also induction of liver enzymes. In pregnancy, drug absorption can be impaired because of reduced gastric tone and motility. Changes in the activity of enzymes in the liver that play a role in drug metabolism, blood flow, and drug transporters can affect the hepatic clearance of antiepileptic drugs. This is very important because some antiepileptic drugs are metabolized by Nicotinamide Adenine Dinucleotide Phosphate (NADPH) cytochrome P450 reductase, Uridine Diphosphatase Glucose (UDP) glucuronosyltransferase, and then excreted via the kidneys [21]. The risk of death from pregnancy in a woman is ten times greater for those who have a history of epilepsy than for those who don't. Aside from that, it has been reported that as many as 12 out of 14 cases of maternal death that occurred from 2009 to 2012, were classified as a Sudden Unexpected Death in Epilepsy (SUDEP) with uncontrolled seizures being the main cause [6].

Therefore, out of consideration of their own health and that of their child, women who have a history of epilepsy are strongly advised to continue their treatment with antiepileptic drugs during their pregnancy. According to a study conducted by Schmidt and Schachter which stated that although about two-thirds of pregnant women with epilepsy do not have seizures during their pregnancy, the dosage of anti-epileptic drugs need to be adjusted as pregnancy goes on, particularly if seizures occur during the first 3 months of pregnancy [5].

Discussion Effects of valproic acid in pregnancy

There are only few prospective studies on the effects of valproic acid during pregnancy, however many cohort studies

have demonstrated a 7-fold increased risk of congenital malformations in women using this medication during the first trimester of pregnancy [22]. When compared to individuals who were not receiving antiepileptic medications, patients who received valproic acid as a monotherapy in the first trimester had a significantly higher risk of spina bifida, craniosynostosis, cleft palate, hypospadias, atrial septal defect, and polydactyly [23,24]. According to estimates, these risks affect 10%–11% of newborn from women with epilepsy, compared to just 2%–3% of the general population. The causes of these teratogenic reactions are not fully elucidated, but may include epigenetic alterations, such as inhibition of histone dehydrogenase with associates with alterations in gene expression, heightened oxidative stress, or inhibition of folate, which is necessary for DNA synthesis [25,26].

In addition to its teratogenic effects, valproic acid can cause various problems after birth. Some studies say that between 30% and 40% of children who has been exposed to valproic acid since the second and the third trimester of pregnancy can lead to cause alterations in cognitive functioning and behaviour, and also a higher chance of having neurological disorders, particularly ADHD and ASD [27]. According to research conducted in Denmark, the probability of ASD in children exposed to valproic acid is 3 times-5 times higher than in the general population. Cohen et al. also identified the chance of developing Attention Deficit Hyperactivity Disorder (ADHD) in 21% of children ages 6 years and above who had been exposed to prenatal valproic acid [28,29]. Furthermore, in a 2004 retrospective study, it was concluded that prenatal intake of valproic acid may have an impact on the intellectual development of children where these children had significantly lower verbal intelligence (IQ) scores than those exposed to carbamazepine, phenytoin, or those who were never expose to any antiepileptic drugs [30]. Several factors may contribute to the clinical effect for mothers and children expose to valproic acid, namely the frequency and duration of seizures, the need for additional drug treatments to control epilepsy, the use of drugs and alcohol, comorbidities, sociocultural factors, and also the stage of pregnancy the woman is in [5].

It is recommended to discontinue treatment with valproic acid during pregnancy, particularly during the initial trimester. Nevertheless, there are some potential risks associated with the discontinuation of this drug in patients with well controlled epilepsy [5]. The EURAP study showed that the discontinuation of therapy in the initial trimester (the most teratogenic trimester) was associated with significantly higher rates of generalized tonic-clonic seizure (33%) compared to the continuation of treatment (16%). It is even more concerning to note that the prevalence of seizures may be increased (29%) when valproic acid is switched to another anti-epileptic drug [31]. The prevention of major birth defects in the fetus can be achieved by administering folic acid supplements, but in the case of women with epilepsy, there is still not enough data to determine its effectiveness. However, giving folic acid is still recommended for all women of reproductive age with or

without epilepsy before conception and during pregnancy at a dose of 0.4 mg per day [32].

In users of valproic acid it is also recommended to check serum alpha-fetoprotein levels (at week 14-16 of pregnancy), ultrasound examination (at week 16-20 of pregnancy) and amniocentesis to check levels of alpha-fetoprotein and anticholinesterase in amniotic fluid [21]. If there are abnormalities in any of the examinations above, continuing the pregnancy or not has to be considered thoroughly. Use of the lowest possible daily dose divided into 3 doses to minimize fluctuations in serum valproic acid levels can also lower the risk of fetal harm. It has been observed that higher daily doses of 1000 mg or more, as well as combination with other therapy (polytherapy), are related to a greater risk of teratogenicity. Additionally, it has been observed that certain other antiepileptic drugs may enhance the teratogenicity of valproic acids. Therefore, if it is necessary to use valproic acid during pregnancy, the most effective dosage should be prescribed in 2 to 3 doses, and ideally as a monotherapy [25].

Conclusion

Using valproic acid in pregnant women with epilepsy is a growing problem. Valproic acid has the highest teratogenic risk compared to other antiepileptic drugs. Not only that, postnatal abnormalities in the form of cognitive and behavioural abnormalities can also be experienced by foetuses exposed to valproic acid. In summary, it is highly recommended to minimize or even discontinue valproic acid use in pregnancy, but in some cases, the risks of discontinuing this drug may outweigh the benefits. Therefore, patients and doctors will be faced with a situation where they must consider in detail the benefits and risks of using this drug.

Acknowledgement

None.

Conflict of Interest

Authors have no conflict of interest to declare.

References

1. T. Tomson, D. Battino, E. Perucca, Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug, *Lancet Neurol*, 15(2016):210-218.
2. M. Rahman, H. Nguyen, Valproic acid-statpearls, *Stat-Pearls*, 2022.
3. E. Perucca, Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience, *CNS Drugs*, 16(2002):695-714.
4. T. Glauser, E. Ben-Menachem, B. Bourgeois, A. Cnaan, C. Guerreiro, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes, *Epilepsia*, 54(2013):551-563.
5. A. Macfarlane, T. Greenhalgh, Sodium valproate in pregnancy: What are the risks and should we use a shared decision-making approach? *BMC Pregnancy Childbirth*, 18(2018):200.
6. Royal College of Obstetrician and Gynecologists, Epilepsy in pregnancy (green-top guideline No. 68), 2016.
7. C.L. Harden, J. Hopp, T.Y. Ting, P.B. Pennell, J.A. French, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American academy of neurology and the American epilepsy society, *Epilepsia*, 50(2009):1229-1236.
8. I. Petersen, S.L. Collings, R.L. McCrea, I. Nazareth, D.P. Osborn, et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: Comparative prevalence studies, *Clin Epidemiol*, 9(2017):95-103.
9. T. Tomson, A. Marson, P. Boon, M.P. Canevini, A. Covanis, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential, *Epilepsia*, 56(2015):1006-1019.
10. EURAP Study Group, Seizure control and treatment in pregnancy: Observations from the EURAP epilepsy pregnancy registry, *Neurology*, 66(2006):354-60.
11. A. Wieck, S. Jones, Dangers of valproate in pregnancy, *BMJ*, 11(2018):361.
12. W. Löscher, Basic pharmacology of valproate a review after 35 years of clinical use for the treatment of epilepsy, *CNS Drugs*, 16(2002):669-94.
13. S.A. Brodie, J.C. Brandes, Could valproic acid be an effective anticancer agent? The evidence so far, *Expert Rev Anticancer Ther*, 14(2014):1097-1100.
14. B. Katzung, Basic & clinical pharmacology, 13th ed, (Trevor A, ed.), McGraw Hill; 2015.
15. L. Brunton, R. Hilal-Dandan, Goodman & Gilman's: The pharmacological basis of therapeutics, 13th ed, (Knollmann B, ed.), McGraw-Hill, 2017.
16. A.G. Marson, A.M. Al-Kharusi, M. Alwaidh, R. Appleton, G.A. Baker, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial, *Lancet*, 369(2007):1016-1026.
17. E. Trinka, J. Höfler, A. Zerbs, F. Brigo, Efficacy and safety of intravenous valproate for status epilepticus: A systematic review, *CNS Drugs*, 28(2014):623-639.
18. S. Thomas, Management of epilepsy and pregnancy, *J Postgrad Med*, 52(2006):57-64.
19. S.I. Patel, P.B. Pennell, Management of epilepsy during pregnancy: An update, *Ther Adv Neurol Disord*, 9(2016):118-129.

20. H. Harsono, Seizure threshold, hormones and anti-epileptic drugs, *Universa Medicina*, 27(2008): 18-28.
21. Fidelia, J. Nainggolan, *Epilepsi dalam kehamilan*, *Medicinus*, 7(2018):61-69.
22. D. Wyszynski, M. Nambisan, T. Surve, R. Alsdorf, C. Smith, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy, *Neurology*, 64(2005):961-5.
23. J. Jentink, M.A. Loane, H. Dolk, I. Barisic, E. Garne, et al. Valproic acid monotherapy in pregnancy and major congenital malformations, *N Engl J Med*, 362(2010):2185-93.
24. K. Meador, M.W. Reynolds, S. Crean, K. Fahrback, C. Probst, Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts, *Epilepsy Res*, 81(2008):1-13.
25. A. Ornoy, Valproic acid in pregnancy: How much are we endangering the embryo and fetus? *Reprod Toxicol*, 28(2009):1-10.
26. A. Semmler, C. Frisch, C. Bleul, D. Smith, L. Bigler, et al. Intrauterine valproate exposure is associated with alterations in hippocampal cell numbers and folate metabolism in a rat model of valproate teratogenicity, *Seizure*, 46(2017):7-12.
27. B. Boobalan, P. Kantharaj, D. Sandhanasamy, S. Mohamad, S. Muthupandian, et al. Early cognitive development in children born to women with epilepsy: A prospective report, *Epilepsia*, 51(2010):2058-2065.
28. J. Christensen, T.K. Grønberg, M. Merete, D. Schendel, E.T. Parner, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism, *JAMA*, 309(2013):1696-1703.
29. M.J. Cohen, K.J. Meador, N. Browning, R. May, G.A. Baker, et al. Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years, *Epilepsy Behav*, 29(2013):308-315.
30. N. Adab, U. Kini, J. Vinten, J. Ayres, G. Baker, et al. The longer term outcome of children born to mothers with epilepsy, *J Neurol Neurosurg Psychiatry*, 75(2004):1575-1583.
31. T. Tomson, D. Battino, E. Bonizzoni, J. Craig, D. Lindhout, et al. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP, *Epilepsia*, 57(2016):e173-e177.
32. Neonatal M, Epilepsy and pregnancy management, *Community of Practice*.

Effects of Valproic Acid on Pregnancy in Epilepsy Patients

ORIGINALITY REPORT

11%

SIMILARITY INDEX

5%

INTERNET SOURCES

11%

PUBLICATIONS

5%

STUDENT PAPERS

PRIMARY SOURCES

1

bmcpregnancychildbirth.biomedcentral.com

Internet Source

2%

2

Jacqueline Acosta-García, Juan C. Jiménez, Florencio Miranda. " Additive Effects of Coadministration of A Receptor Agonist CGS-21680 and mGluR5 Antagonist MPEP on the Development and Expression of Methamphetamine-Induced Locomotor Sensitization in Rats ", Journal of Drug and Alcohol Research, 2017

Publication

2%

3

Manuchair Ebadi. "Desk Reference of Clinical Pharmacology", CRC Press, 2019

Publication

2%

4

Submitted to University of Wales Institute, Cardiff

Student Paper

1%

5

Louis A. Pagliaro, Ann Marie Pagliaro. "Psychologists' Psychotropic Drug Reference", Routledge, 2020

Publication

1%

6

Sima I. Patel, Page B. Pennell. "Management of epilepsy during pregnancy: an update", Therapeutic Advances in Neurological Disorders, 2015

Publication

1%

7

"de Swiet's Medical Disorders in Obstetric Practice", Wiley, 2010

Publication

1%

8	Submitted to Universitas Airlangga Student Paper	1 %
9	Submitted to CSU, Los Angeles Student Paper	1 %
10	"Evidence-based Obstetrics and Gynecology", Wiley, 2019 Publication	<1 %
11	Torbjörn Tomson, Dina Battino, Emilio Perucca. "Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug", The Lancet Neurology, 2016 Publication	<1 %
12	dspace.ut.ee Internet Source	<1 %
13	ijmcmed.org Internet Source	<1 %

Exclude quotes Off Exclude matches < 10 words
 Exclude bibliography On

Effects of Valproic Acid on Pregnancy in Epilepsy Patients

GRADEMARK REPORT

FINAL GRADE

GENERAL COMMENTS

/0

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5